{"schema_version":"secwatch.filing_event.v1","accession":"0001171843-25-001049","form_type":"8-K","ticker":"ABUS","cik":"0001447028","company_name":"Arbutus Biopharma Corp","filed_at":"2025-02-25T23:59:59+00:00","discovered_at":"2026-05-14T18:03:03.649422+00:00","generated_at":"2026-05-26T04:41:47.993643+00:00","sec_items":["5.02","8.01","9.01"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Arbutus appoints Roivant-affiliated CEO and new board after all prior directors resign","bullets":["All seven directors resigned Feb 24; board reduced to five with new appointees including Roivant affiliates.","Lindsay Androski named President and CEO, replacing interim CEO McElhaugh; she also serves as board chair.","Androski receives $515k salary, 45% target bonus, and ~$750k option grant; three new directors are from Roivant.","Company will pause investor meetings to review strategic options for hepatitis B pipeline and development plans."],"urls":{"canonical":"https://secwatch.observer/filing/0001171843-25-001049","json":"https://secwatch.observer/filing/0001171843-25-001049.json","markdown":"https://secwatch.observer/filing/0001171843-25-001049.md","text":"https://secwatch.observer/filing/0001171843-25-001049.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1447028/000117184325001049/0001171843-25-001049-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1447028/000117184325001049/f8k_022525.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-26T04:41:47.993643+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"0039c3ab3c","claim":"Daniel Burgess resigned as Director at Arbutus Biopharma Corp.","evidence_excerpt":"Daniel Burgess","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1447028/000117184325001049/0001171843-25-001049-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"resigned"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"},{"claim_id":"25ffe201a5","claim":"Lindsay Androski was appointed as Chief Executive Officer at Arbutus Biopharma Corp.","evidence_excerpt":"Ms. Androski, as Chief Executive Officer of the Company, will not receive compensation for her service as a director.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1447028/000117184325001049/0001171843-25-001049-index.htm","confidence":0.85,"family_label":"Executive change","details":[{"label":"Role","value":"Chief Executive Officer"}],"fact_type":"executive_change"},{"claim_id":"a6603cf303","claim":"James Meyers resigned as Director at Arbutus Biopharma Corp.","evidence_excerpt":"James Meyers","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1447028/000117184325001049/0001171843-25-001049-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"resigned"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"},{"claim_id":"accfbf2ca9","claim":"Richard C. Henriques resigned as Director at Arbutus Biopharma Corp.","evidence_excerpt":"Richard C. Henriques","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1447028/000117184325001049/0001171843-25-001049-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"resigned"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"},{"claim_id":"add14f833b","claim":"Frank Torti resigned as Director at Arbutus Biopharma Corp.","evidence_excerpt":"Frank Torti, M.D., chairperson of the Board","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1447028/000117184325001049/0001171843-25-001049-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"resigned"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"},{"claim_id":"c1d90953b3","claim":"Melissa V. Rewolinski resigned as Director at Arbutus Biopharma Corp.","evidence_excerpt":"Melissa V. Rewolinski, Ph.D.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1447028/000117184325001049/0001171843-25-001049-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"resigned"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"},{"claim_id":"c5ece88909","claim":"Keith Manchester resigned as Director at Arbutus Biopharma Corp.","evidence_excerpt":"Keith Manchester, M.D.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1447028/000117184325001049/0001171843-25-001049-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"resigned"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"},{"claim_id":"cb52a38c7f","claim":"Lindsay Androski was appointed as Chairperson of the Board at Arbutus Biopharma Corp.","evidence_excerpt":"appointed Ms. Androski as chairperson of the Board","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1447028/000117184325001049/0001171843-25-001049-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Chairperson of the Board"}],"fact_type":"executive_change"},{"claim_id":"dbcb8bed68","claim":"Michael J. McElhaugh resigned as Director at Arbutus Biopharma Corp.","evidence_excerpt":"Michael J. McElhaugh","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1447028/000117184325001049/0001171843-25-001049-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"resigned"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}